Antibody treatment for infants living with HIV
Part of Infections clinical trials.
This trial tests a new antibody medication given as a shot to babies with HIV. It aims to help control the virus and may be an option for infants who are newly diagnosed or starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is between 1 month and 12 months old (1 to 365 days old) at the time of joining.
- Your baby has tested positive for HIV using a blood test that detects the virus's genetic material.
- Your baby has not yet started HIV medications, or has been on them for no more than 30 days (not counting preventive medicine given at birth).
- Your baby is stable enough to be cared for at home, not needing to stay in the hospital.
- You or your baby's legal guardian can give permission for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a special antibody treatment to babies living with HIV, shortly after birth, can help their immune system fight the virus better. It aims to improve their long-term health.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.